All In Biotech

Drug Trial Radar · NCT06671977

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Phase 1 Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Deepak C. D'SouzaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

Conditions

  • Major Depression Disorder
  • Depression

Interventions

  • DMT-Medium DoseDrug

    14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

  • DMT-Low DoseDrug

    10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

  • THC-Medium DoseDrug

    0.5 mg over 5 minutes and then 2 mg over and 55 minutes

  • THC-Low DoseDrug

    0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Physiological indicesTime frame: Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.
  2. Psychedelic EffectsTime frame: From start Test Day Time points (Minutes): -60, +30, +120.
  3. Psychotomimetic EffectsTime frame: Test Day Time points (Minutes): -60, +30, +120
  4. AnxietyTime frame: Test Day Time points (Minutes): -60, +30, +120
  5. DepressionTime frame: From start of test day (-60), +30, and +120.
  6. Intensity of the ExperienceTime frame: Test Day Time points (Minutes): +150 - +180
  7. Drug Reinforcing EffectsTime frame: Test Day Time points (Minutes): +120
  8. Tolerability of Overt Adverse EffectsTime frame: Test Day Time points (Minutes): -60, +30, +120, 180 (end of test day)
  9. ElectrophysiologicalTime frame: Resting State EEG: Will be collected the day after each dosing session. [Time Frame: -60 minutes before DMT administration until +180 minutes after DMT administration].

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,

    West Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.